共 50 条
- [31] A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of unclear export (SINE) in patients (pis) with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Mau-Soerensen, MortenRazak, Albiruni R. A.Shields, Anthony FrankGabrall, Nashat Y.Gereeltano, John F.Shacham, SharonLassen, Ulrlk NielsRashal, TamlCooksoy, JenniferLandosman, YosofPond, GregoryOza, Amit M.Kauffman, MichaelSiu, Lillian L.Bedard, Philippe L.Mahaseth, HemchandraMlrza, Mansoor RazaMahipal, Arnit
- [32] SAFETY AND EFFICACY OF BEVACIZUMAB PLUS TTFIELDS IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM): DATA FROM A PHASE II CLINICAL TRIALNEURO-ONCOLOGY, 2019, 21 : 18 - 18Fallah, JalehChaudhary, RekhaRogers, LisaWei, WeiBrewer, CathyPeereboom, DavidAhluwalia, Manmeet
- [33] Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Reardon, David A.Dietrich, JorgKaley, Thomas JosephGan, Hui KongDunn, Gavin P.Cloughesy, Timothy FrancisLim, MichaelClarke, Jennifer LeighPark, Andrew J.Pan, Linda S.Lai, Dominic W.Karakunnel, Joyson JosephRobbins, Paul B.Narwal, RajeshVenhaus, Ralph Rudolph
- [34] Phase I study of gefitinib and rapamycin in patients with recurrent or progressive glioblastoma (Gbm).JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 132S - 132SDas, ABadruddoja, MTryciecky, DYu, JBlack, K
- [35] PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH GLIOBLASTOMA (GBM): RESULTS FOR COHORT B (DUR MONOTHERAPY), BEVACIZUMAB (BEV) NAIVE PATIENTS WITH RECURRENT GBMNEURO-ONCOLOGY, 2016, 18 : 18 - 18Reardon, DavidKaley, ThomasDietrich, JorgLim, MichaelDunn, GavinGan, HuiCloughesy, TimothyClarke, JenniferPark, AndrewMacri, MaryRyan, AileenRicciardi, ToniReddy, VijayVenhaus, Ralph
- [36] THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SELINEXOR (KPT-330) ACTIVITY IN DOUBLE HIT DIFFUSE LARGE B CELL LYMPHOMAS (DLBCL) IN PRECLINICAL MODELS & CLINICAL ACTIVITY IN PATIENTS WITH DLBCLHAEMATOLOGICA, 2014, 99 : 152 - 152Kuruvilla, J.Cerchietti, L.Wagner-Johnston, N.Stone, R.Jacobsen, E.Mau-Sorensen, M.Brown, P.Baz, R.Shal, B.Flynn, J.Flinn, I.Kukreti, V.Tiedemann, R.Goy, A.Landesman, Y.Klebanov, B.Shacham, E.Saint-Martin, J. R.Marshall, T.McCartney, J.McCauley, D.Carlson, R.Rebello, S.Rashal, T.Mirza, M. R.Shacham, S.Kauffman, M.Gutierrez, M.
- [37] EFFICACY AND SAFETY OF BEVACIZUMAB (BV) AND IRINOTECAN (I) IN ELDERLY PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORM (GBM): A MONOCENTRIC RETROSPECTIVE STUDYANNALS OF ONCOLOGY, 2014, 25Robert, M.Leux, C.Gourmelon, C.Campone, M.Frenel, J.
- [38] Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Reardon, David A.Kaley, Thomas JosephDietrich, JorgClarke, Jennifer LeighDunn, Gavin P.Lim, MichaelCloughesy, Timothy FrancisGan, Hui KongPark, Andrew J.Schwarzenberger, PaulRicciardi, ToniMacri, Mary J.Ryan, AileenVenhaus, Ralph Rudolph
- [39] PHASE 2 SAFETY AND EFFICACY OF AR-67 (7-T-BUTYLDIMETHYLSILTYL-10-HYDROXYCAMPTOTHECIN) IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM) OR GLIOSARCOMANEURO-ONCOLOGY, 2019, 21 : 22 - 22Kumthekar, PriyaRaizer, JeffreyCavaliere, RobertDevoe, CraigJensen, RandyStieber, VolkerRunk, TinaGrewal, JaiBrownell, EliseZukiwski, AlexProniuk, StefanArnold, SusanneVredenburgh, James
- [40] A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastomaNEURO-ONCOLOGY, 2011, 13 (04) : 437 - 446Wen, Patrick Y.Schiff, DavidCloughesy, Timothy F.Raizer, Jeffrey J.Laterra, JohnSmitt, MelanieWolf, MichaelOliner, Kelly S.Anderson, AbrahamZhu, MinLoh, ElwynReardon, David A.